Shu Taishen announced that the subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. pharmaceutical Bojianing added clinical trial applications for treatment of major surgical bleeding. The application was recently accepted by the State Drug Administration. The acceptance number is CXSL2601019. The application stage is clinical.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.